Conning Inc. Incyte Corp Transaction History

Conning Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 23, 2021	SELL	$76.02 - $100.5 $182,828 - $241,702	-2,405 Closed	0 $0
Q4 2020 Jan 28, 2021	SELL	$80.74 - $97.7 $12,918 - $15,632	-160 Reduced 6.24%	2,405 $209,000
Q3 2020 Oct 21, 2020	BUY	$85.07 - $109.69 $1,701 - $2,193	20 Added 0.79%	2,565 $230,000
Q2 2020 Aug 07, 2020	BUY	$74.18 - $108.93 $188,788 - $277,226	2,545 New	2,545 $265,000
Q1 2020 Apr 29, 2020	SELL	$63.18 - $85.97 $151,632 - $206,328	-2,400 Closed	0 $0
Q4 2019 Jan 29, 2020	BUY	$73.04 - $95.72 $175,296 - $229,728	2,400 New	2,400 $210,000
Q3 2019 Oct 30, 2019	SELL	$72.82 - $86.52 $172,583 - $205,052	-2,370 Closed	0 $0
Q2 2019 Jul 25, 2019	SELL	$73.52 - $88.7 $25,732 - $31,045	-350 Reduced 12.87%	2,370 $201,000
Q1 2019 Apr 22, 2019	BUY	$63.56 - $88.17 $172,883 - $239,822	2,720 New	2,720 $234,000
Q3 2018 Oct 26, 2018	SELL	$61.75 - $74.23 $203,157 - $244,216	-3,290 Closed	0 $0
Q1 2018 May 04, 2018	BUY	$83.06 - $100.98 $14,950 - $18,176	180 Added 5.79%	3,290 $274,000
Q4 2017 Jan 30, 2018	BUY	$93.56 - $116.6 $99,173 - $123,596	1,060 Added 51.71%	3,110 $295,000
Q3 2017 Oct 20, 2017	BUY	$109.15 - $138.27 $223,757 - $283,453	2,050	2,050 $239,000

657

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Conning Inc., based on Form 13F filings with the SEC.

Stay updated on Conning Inc. with notifications on news.